Literature DB >> 23624566

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Annie Killoran1, Kevin M Biglan, Joseph Jankovic, Shirley Eberly, Elise Kayson, David Oakes, Anne B Young, Ira Shoulson.   

Abstract

OBJECTIVES: We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study.
METHODS: The Prospective Huntington At Risk Observational Study (PHAROS) enrolled adults at risk for Huntington disease (HD). They were assessed approximately every 9 months with the Unified Huntington's Disease Rating Scale (UHDRS) by investigators unaware of participants' gene status. UHDRS scores were compared according to the Huntingtin gene CAG repeat number: expanded >36, intermediate 27-35, and nonexpanded controls <26.
RESULTS: Fifty (5.1%) of the 983 participants had an intermediate allele (IA). They were similar to controls on UHDRS motor, cognitive, and functional measures, but significantly worse behaviorally on apathy and suicidal ideation. On 5 of the 9 other behavioral items and on total behavior, the IA group's scores were worse than those of controls and expanded participants, who themselves scored significantly worse than controls on 6 behavioral measures. Retention rates at 4 years were 48% for the IA group compared to 58% and 60% for the expanded and control groups.
CONCLUSIONS: In a cohort at risk for HD, the IA was associated with significant behavioral abnormalities but normal motor and cognition. This behavioral phenotype may represent a prodromal stage of HD, with the potential for subsequent clinical manifestations, or be part of a distinct phenotype conferred by pathology independent of the CAG expansion length.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624566      PMCID: PMC3716408          DOI: 10.1212/WNL.0b013e318294b304

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  New problems in testing for Huntington's disease: the issue of intermediate and reduced penetrance alleles.

Authors:  A Maat-Kievit; M Losekoot; H Van Den Boer-Van Den Berg; G J Van Ommen; M Niermeijer; M Breuning; A Tibben
Journal:  J Med Genet       Date:  2001-04       Impact factor: 6.318

2.  Premature ovarian failure among fragile X premutation carriers: parent-of-origin effect?

Authors:  S L Sherman
Journal:  Am J Hum Genet       Date:  2000-06-12       Impact factor: 11.025

3.  Treatment of Apathy in Huntington's Disease and Other Movement Disorders.

Authors:  Ashok Krishnamoorthy; David Craufurd
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

4.  Specific psychiatric manifestations among preclinical Huntington disease mutation carriers.

Authors:  Jeanine Marshall; Kerry White; Marjorie Weaver; Leah Flury Wetherill; Siu Hui; Julie C Stout; Shannon A Johnson; Xabier Beristain; Jacqueline Gray; Joanne Wojcieszek; Tatiana Foroud
Journal:  Arch Neurol       Date:  2007-01

5.  Correlates of apathy in Huntington's disease.

Authors:  E van Duijn; N Reedeker; E J Giltay; R A C Roos; R C van der Mast
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

6.  At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled.

Authors: 
Journal:  Arch Neurol       Date:  2006-07

7.  Technical standards and guidelines for Huntington disease testing.

Authors:  Nicholas T Potter; Elaine B Spector; Thomas W Prior
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

Review 8.  The fragile-X premutation: a maturing perspective.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Am J Hum Genet       Date:  2004-03-29       Impact factor: 11.025

9.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

Authors:  Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

10.  Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT.

Authors:  Ainhi D Ha; Christopher A Beck; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-02-02
View more
  22 in total

1.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

2.  Neurodegenerative disease: 'fifty shades of grey' in the Huntington disease gene.

Authors:  Ferdinando Squitieri
Journal:  Nat Rev Neurol       Date:  2013-06-25       Impact factor: 42.937

3.  Clinical utility gene card for: Huntington's disease.

Authors:  Carsten Saft; Blair R Leavitt; Jörg T Epplen
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

4.  CAG repeat size in Huntingtin alleles is associated with cancer prognosis.

Authors:  Morgane Sonia Thion; Sophie Tézenas du Montcel; Jean-Louis Golmard; Sophie Vacher; Laure Barjhoux; Valérie Sornin; Cécile Cazeneuve; Ivan Bièche; Olga Sinilnikova; Dominique Stoppa-Lyonnet; Alexandra Durr; Sandrine Humbert
Journal:  Eur J Hum Genet       Date:  2016-03-16       Impact factor: 4.246

5.  Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD.

Authors:  Nancy R Downing; Spencer Lourens; Isabella De Soriano; Jeffrey D Long; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2016-12-15

6.  Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene.

Authors:  Peter K Panegyres; Chen-Chun Shu; Huei-Yang Chen; Jane S Paulsen
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

7.  Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregation.

Authors:  Elodie Monsellier; Virginie Redeker; Gemma Ruiz-Arlandis; Luc Bousset; Ronald Melki
Journal:  J Biol Chem       Date:  2014-12-10       Impact factor: 5.157

Review 8.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

Review 9.  Huntington's Disease: Relationship Between Phenotype and Genotype.

Authors:  Yi-Min Sun; Yan-Bin Zhang; Zhi-Ying Wu
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

10.  Whole-Brain Connectivity in a Large Study of Huntington's Disease Gene Mutation Carriers and Healthy Controls.

Authors:  Flor A Espinoza; Jessica A Turner; Victor M Vergara; Robyn L Miller; Eva Mennigen; Jingyu Liu; Maria B Misiura; Jennifer Ciarochi; Hans J Johnson; Jeffrey D Long; Henry J Bockholt; Vincent A Magnotta; Jane S Paulsen; Vince D Calhoun
Journal:  Brain Connect       Date:  2018-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.